Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Descartes-15 by Cartesian Therapeutics for Refractory Multiple Myeloma: Likelihood of Approval
Descartes-15 is under clinical development by Cartesian Therapeutics and currently in Phase I for Refractory Multiple Myeloma. According to GlobalData,...
Descartes-15 by Cartesian Therapeutics for Relapsed Multiple Myeloma: Likelihood of Approval
Descartes-15 is under clinical development by Cartesian Therapeutics and currently in Phase I for Relapsed Multiple Myeloma. According to GlobalData,...
Descartes-08 by Cartesian Therapeutics for Systemic Lupus Erythematosus: Likelihood of Approval
Descartes-08 is under clinical development by Cartesian Therapeutics and currently in Phase II for Systemic Lupus Erythematosus. According to GlobalData,...
Descartes-15 by Cartesian Therapeutics for Autoimmune Disorders: Likelihood of Approval
Descartes-15 is under clinical development by Cartesian Therapeutics and currently in Phase I for Autoimmune Disorders. According to GlobalData, Phase...
Descartes-08 by Cartesian Therapeutics for Myasthenia Gravis: Likelihood of Approval
Descartes-08 is under clinical development by Cartesian Therapeutics and currently in Phase II for Myasthenia Gravis. According to GlobalData, Phase...
Descartes-11 by Cartesian Therapeutics for Refractory Multiple Myeloma: Likelihood of Approval
Descartes-11 is under clinical development by Cartesian Therapeutics and currently in Phase II for Refractory Multiple Myeloma. According to GlobalData,...
Descartes-11 by Cartesian Therapeutics for Relapsed Multiple Myeloma: Likelihood of Approval
Descartes-11 is under clinical development by Cartesian Therapeutics and currently in Phase II for Relapsed Multiple Myeloma. According to GlobalData,...